부산대학교 도서관

The article discusses the findings of the PREVeNT trial, which examined the use of preventative vigabatrin treatment in infants with tuberous sclerosis complex (TSC). The study found a reduced incidence of infantile spasms but not focal seizures, which aligns with the authors' clinical experience. However, the absence of improved cognitive development was a disappointing outcome. The authors suggest that the control groups in the study had better developmental outcomes due to close monitoring and expert management of seizures. They also raise concerns about the potential negative impacts of vigabatrin on cognitive development and suggest that a shorter duration of treatment may be more beneficial. Overall, the authors emphasize the importance of active management of infants with TSC to minimize the effects of seizures and optimize cognitive outcomes. [Extracted from the article]